Drug Research
APP Pharmaceuticals receives marketing approval for Methotrexate Injection
APP Pharmaceuticals, a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals, has received FDA approval to market preservative-free Methotrexate Injection, USP. ...
Drug Research
Ranbaxy launches cholesterol reducing drug in Australia
Ranbaxy Australia, a subsidiary of Ranbaxy Laboratories, has introduced Atorvastatin 10mg, 20mg, 40mg and 80mg tablets after receiving approval from Therapeutic Goods Administration (TGA)...
Drug Research
La Jolla buys GCS-100 rights from Solana
La Jolla Pharmaceutical Company has acquired global development and commercialization rights to GCS-100 from Solana Therapeutics. GCS-100 is an inhibitor...
Drug Research
Novartis receives Morrison & Foerster advice on Camurus deal
The global law firm, Morrison & Foerster has advised Novartis to sign an exclusive collaboration, option and license agreement with Camurus, a Swedish research-based...
Drug Research
Mymetics regains intra-nasal influenza vaccine from Solvay
Mymetics, a developer of next-generation preventative vaccines, has regained its intra-nasal influenza vaccine from Solvay.Mymetics has provided license of its intra-nasal flu vaccine, under which...
Drug Research
The Medicines Company introduces new Cleviprex formulation
The Medicines Company has launched a new twelve hour formulation for the FDA approved Cleviprex Injectable Emulsion.Cleviprex is an intravenous dihydropyridine calcium channel blocker, which...
Drug Research
Theraclone doses first patient in Phase 1 TCN-032 drug...
Theraclone Sciences has dosed first patient in a randomized, double-blind, dose-escalation Phase 1 trial investigating TCN-032 as a treatment for influenza A virus. ...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.